Human influenza vaccines and assessment of immunogenicity

References

• Nicholson KG, Wood JM, Zambon M. Influenza. Lancet362(9397), 1733–1745 (2003).
   PubMed Web of Science ®Google Scholar
• Hibbert CL, Piedra PA, McLaurin KK, Vesikari T, Mauskopf J, Mahadevia PJ. Cost–effectiveness of live-attenuated influenza vaccine, trivalent in preventing influenza in young children attending day-care centres. Vaccine25(47), 8010–8020 (2007).
   PubMed Web of Science ®Google Scholar
• Stohr K. Influenza – WHO cares. Lancet Infect. Dis.2(9), 517 (2002).
   PubMed Web of Science ®Google Scholar
• Couch RB. Seasonal inactivated influenza virus vaccines. Vaccine26(Suppl. 4), D5–D9 (2008).
   PubMed Web of Science ®Google Scholar
• Fiore AE, Shay DK, Broder K et al. Prevention and control of seasonal influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm. Rep.58(RR-8), 1–52 (2009).
   PubMedGoogle Scholar
• Treanor JJ, Kotloff K, Betts RF et al. Evaluation of trivalent, live, cold-adapted (CAIV-T) and inactivated (TIV) influenza vaccines in prevention of virus infection and illness following challenge of adults with wild-type influenza A (H1N1), A (H3N2), and B viruses. Vaccine18(9–10), 899–906 (1999).
   PubMed Web of Science ®Google Scholar
• Skowronski DM, Masaro C, Kwindt TL et al. Estimating vaccine effectiveness against laboratory-confirmed influenza using a sentinel physician network: results from the 2005–2006 season of dual A and B vaccine mismatch in Canada. Vaccine25(15), 2842–2851 (2007).
   PubMed Web of Science ®Google Scholar
• Gross PA, Hermogenes AW, Sacks HS, Lau J, Levandowski RA. The efficacy of influenza vaccine in elderly persons. A meta-analysis and review of the literature. Ann. Intern. Med.123(7), 518–527 (1995).
   PubMed Web of Science ®Google Scholar
• Ben-Yehuda A, Danenberg HD, Zakay-Rones Z, Gross DJ, Friedman G. The influence of sequential annual vaccination and of DHEA administration on the efficacy of the immune response to influenza vaccine in the elderly. Mech. Ageing Dev.102(2–3), 299–306 (1998).
   PubMed Web of Science ®Google Scholar
• Engelhard D, Nagler A, Hardan I et al. Antibody response to a two-dose regimen of influenza vaccine in allogeneic T cell-depleted and autologous BMT recipients. Bone Marrow Transplant.11(1), 1–5 (1993).
   PubMed Web of Science ®Google Scholar
• Admon D, Engelhard D, Strauss N, Goldman N, Zakay-Rones Z. Antibody response to influenza immunization in patients after heart transplantation. Vaccine15(14), 1518–1522 (1997).
   PubMed Web of Science ®Google Scholar
• Jefferson T, Di Pietrantonj C, Al-Ansary LA, Ferroni E, Thorning S, Thomas RE. Vaccines for preventing influenza in the elderly. Cochrane Database Syst. Rev.2, CD004876 (2010).
   PubMedGoogle Scholar
• Smith DJ, Lapedes AS, de Jong JC et al. Mapping the antigenic and genetic evolution of influenza virus. Science (NY)305(5682), 371–376 (2004).
   PubMed Web of Science ®Google Scholar
• Zhou NN, Senne DA, Landgraf JS et al. Genetic reassortment of avian, swine, and human influenza A viruses in American pigs. J. Virol.73(10), 8851–8856 (1999).
   PubMed Web of Science ®Google Scholar
• Barr IG, Komadina N, Hurt AC et al. An influenza A(H3) reassortant was epidemic in Australia and New Zealand in 2003. J. Med. Virol.76(3), 391–397 (2005).
   PubMed Web of Science ®Google Scholar
• Holmes EC, Ghedin E, Miller N et al. Whole-genome analysis of human influenza A virus reveals multiple persistent lineages and reassortment among recent H3N2 viruses. PLoS Biol.3(9), e300 (2005).
   Web of Science ®Google Scholar
• Mossad SB. 2008–2009 Influenza update: a better vaccine match. Cleve. Clin. J. Med.75(12), 865–870 (2008).
   PubMed Web of Science ®Google Scholar
• de Jong JC, Beyer WE, Palache AM, Rimmelzwaan GF, Osterhaus AD. Mismatch between the 1997/1998 influenza vaccine and the major epidemic A(H3N2) virus strain as the cause of an inadequate vaccine-induced antibody response to this strain in the elderly. J. Med. Virol.61(1), 94–99 (2000).
   PubMed Web of Science ®Google Scholar
• Palese P, Garcia-Sastre A. Influenza vaccines: present and future. J. Clin. Invest.110(1), 9–13 (2002).
   PubMed Web of Science ®Google Scholar
• Wood JM. Selection of influenza vaccine strains and developing pandemic vaccines. Vaccine20(Suppl. 5), B40–B44 (2002).
   PubMed Web of Science ®Google Scholar
• Russell CA, Jones TC, Barr IG et al. Influenza vaccine strain selection and recent studies on the global migration of seasonal influenza viruses. Vaccine26(Suppl. 4), D31–D34 (2008).
   PubMed Web of Science ®Google Scholar
• Bianchi E, Liang X, Ingallinella P et al. Universal influenza B vaccine based on the maturational cleavage site of the hemagglutinin precursor. J. Virol.79(12), 7380–7388 (2005).
   PubMed Web of Science ®Google Scholar
• Belshe RB, Coelingh K, Ambrose CS, Woo JC, Wu X. Efficacy of live attenuated influenza vaccine in children against influenza B viruses by lineage and antigenic similarity. Vaccine28(9), 2149–2156 (2010).
   PubMed Web of Science ®Google Scholar
• Francis T, Salk JE, Pearson HE, Brown PN. Protective effect of vaccination against induced influenza A. J. Clin. Invest.24(4), 536–546 (1945).
   PubMed Web of Science ®Google Scholar
• Wood JM, Mumford J, Schild GC, Webster RG, Nicholson KG. Single-radial-immunodiffusion potency tests of inactivated influenza vaccines for use in man and animals. Dev. Biol. Standard.64, 169–177 (1986).
   PubMedGoogle Scholar
• Couch RB, Winokur P, Brady R et al. Safety and immunogenicity of a high dosage trivalent influenza vaccine among elderly subjects. Vaccine25(44), 7656–7663 (2007).
   PubMed Web of Science ®Google Scholar
• Morag A, Levy R, Weil G, Zakay-Rones Z. Clinical and serological response in humans following immunization with Gripax influenza vaccine. J. Med. Virol.11(1), 67–75 (1983).
   PubMed Web of Science ®Google Scholar
• Keitel WA, Atmar RL, Cate TR et al. Safety of high doses of influenza vaccine and effect on antibody responses in elderly persons. Arch. Intern. Med.166(10), 1121–1127 (2006).
   PubMed Web of Science ®Google Scholar
• Falsey AR, Treanor JJ, Tornieporth N, Capellan J, Gorse GJ. Randomized, double-blind controlled Phase 3 trial comparing the immunogenicity of high-dose and standard-dose influenza vaccine in adults 65 years of age and older. J. Infect. Dis.200(2), 172–180 (2009).
   PubMed Web of Science ®Google Scholar
• Maassab HF, Heilman CA, Herlocher ML. Cold-adapted influenza viruses for use as live vaccines for man. Adv. Biotechnol. Process.14, 203–242 (1990).
   PubMedGoogle Scholar
• Cox RJ, Brokstad KA, Ogra P. Influenza virus: immunity and vaccination strategies. Comparison of the immune response to inactivated and live, attenuated influenza vaccines. Scand. J. Immunol.59(1), 1–15 (2004).
   PubMed Web of Science ®Google Scholar
• Buonagurio DA, Bechert TM, Yang CF et al. Genetic stability of live, cold-adapted influenza virus components of the FluMist/CAIV-T vaccine throughout the manufacturing process. Vaccine24(12), 2151–2160 (2006).
   PubMed Web of Science ®Google Scholar
• Vesikari T, Karvonen A, Korhonen T et al. A randomized, double-blind study of the safety, transmissibility and phenotypic and genotypic stability of cold-adapted influenza virus vaccine. Pediatr. Infect. Dis. J.25(7), 590–595 (2006).
   PubMed Web of Science ®Google Scholar
• Buonagurio DA, O’Neill RE, Shutyak L et al. Genetic and phenotypic stability of cold-adapted influenza viruses in a trivalent vaccine administered to children in a day care setting. Virology347(2), 296–306 (2006).
   PubMed Web of Science ®Google Scholar
• Belshe RB, Gruber WC, Mendelman PM et al. Correlates of immune protection induced by live, attenuated, cold-adapted, trivalent, intranasal influenza virus vaccine. J. Infect. Dis.181(3), 1133–1137 (2000).
   PubMed Web of Science ®Google Scholar
• Belshe RB, Nichol KL, Black SB et al. Safety, efficacy, and effectiveness of live, attenuated, cold-adapted influenza vaccine in an indicated population aged 5–49 years. Clin. Infect. Dis.39(7), 920–927 (2004).
   PubMed Web of Science ®Google Scholar
• Belshe RB, Edwards KM, Vesikari T et al. Live attenuated versus inactivated influenza vaccine in infants and young children. N. Engl. J. Med.356(7), 685–696 (2007).
   PubMed Web of Science ®Google Scholar
• Belshe RB, Toback SL, Yi T, Ambrose CS. Efficacy of live attenuated influenza vaccine in children 6 months to 17 years of age. Influenza Other Resp. Viruses4(3), 141–145 (2010).
   PubMed Web of Science ®Google Scholar
• Belyakov IM, Ahlers JD. What role does the route of immunization play in the generation of protective immunity against mucosal pathogens? J. Immunol.183(11), 6883–6892 (2009).
   PubMed Web of Science ®Google Scholar
• Belshe RB, Gruber WC, Mendelman PM et al. Efficacy of vaccination with live attenuated, cold-adapted, trivalent, intranasal influenza virus vaccine against a variant (A/Sydney) not contained in the vaccine. J. Pediatr.136(2), 168–175 (2000).
   PubMed Web of Science ®Google Scholar
• Ambrose CS, Luke C, Coelingh K. Current status of live attenuated influenza vaccine in the United States for seasonal and pandemic influenza. Influenza Other Resp. Viruses2(6), 193–202 (2008).
   PubMed Web of Science ®Google Scholar
• Mendelman PM, Rappaport R, Cho I et al. Live attenuated influenza vaccine induces cross-reactive antibody responses in children against an a/Fujian/411/2002-like H3N2 antigenic variant strain. Pediatr. Infect. Dis. J.23(11), 1053–1055 (2004).
   PubMed Web of Science ®Google Scholar
• Renegar KB, Small PA Jr, Boykins LG, Wright PF. Role of IgA versus IgG in the control of influenza viral infection in the murine respiratory tract. J. Immunol.173(3), 1978–1986 (2004).
   PubMed Web of Science ®Google Scholar
• Bernstein DI, Yan L, Treanor J, Mendelman PM, Belshe R. Effect of yearly vaccinations with live, attenuated, cold-adapted, trivalent, intranasal influenza vaccines on antibody responses in children. Pediatr. Infect. Dis. J.22(1), 28–34 (2003).
   PubMed Web of Science ®Google Scholar
• Murphy BR, Coelingh K. Principles underlying the development and use of live attenuated cold-adapted influenza A and B virus vaccines. Viral Immunol.15(2), 295–323 (2002).
   PubMed Web of Science ®Google Scholar
• Gerhard W, Mozdzanowska K, Zharikova D. Prospects for universal influenza virus vaccine. Emerg. Infect. Dis.12(4), 569–574 (2006).
   PubMed Web of Science ®Google Scholar
• Couch RB. An overview of serum antibody responses to influenza virus antigens. Dev. Biol.115, 25–30 (2003).
   Google Scholar
• Potter CW, Oxford JS. Determinants of immunity to influenza infection in man. Br. Med. Bull.35(1), 69–75 (1979).
   PubMed Web of Science ®Google Scholar
• Gulati U, Kumari K, Wu W, Keitel WA, Air GM. Amount and avidity of serum antibodies against native glycoproteins and denatured virus after repeated influenza whole-virus vaccination. Vaccine23(11), 1414–1425 (2005).
   PubMed Web of Science ®Google Scholar
• Feng J, Gulati U, Zhang X et al. Antibody quantity versus quality after influenza vaccination. Vaccine27(45), 6358–6362 (2009).
   PubMed Web of Science ®Google Scholar
• Nauta JJ, Beyer WE, Osterhaus AD. On the relationship between mean antibody level, seroprotection and clinical protection from influenza. Biologicals37(4), 216–221 (2009).
   PubMed Web of Science ®Google Scholar
• Johansson BE, Kilbourne ED. Immunization with dissociated neuraminidase, matrix, and nucleoproteins from influenza A virus eliminates cognate help and antigenic competition. Virology225(1), 136–144 (1996).
   PubMed Web of Science ®Google Scholar
• Chen Z, Kadowaki S, Hagiwara Y et al. Cross-protection against a lethal influenza virus infection by DNA vaccine to neuraminidase. Vaccine18(28), 3214–3222 (2000).
   PubMed Web of Science ®Google Scholar
• Wu G, Yan S. Prediction of mutation trend in hemagglutinins and neuraminidases from influenza A viruses by means of cross-impact analysis. Biochem. Biophys. Res. Commun.326(2), 475–482 (2005).
   PubMed Web of Science ®Google Scholar
• Kilbourne ED, Johansson BE, Grajower B. Independent and disparate evolution in nature of influenza A virus hemagglutinin and neuraminidase glycoproteins. Proc. Natl Acad. Sci. USA87(2), 786–790 (1990).
   PubMed Web of Science ®Google Scholar
• Sandbulte MR, Jimenez GS, Boon AC, Smith LR, Treanor JJ, Webby RJ. Cross-reactive neuraminidase antibodies afford partial protection against H5N1 in mice and are present in unexposed humans. PLoS Med.4(2), e59 (2007).
   PubMed Web of Science ®Google Scholar
• Chen Z, Yoshikawa T, Kadowaki S et al. Protection and antibody responses in different strains of mouse immunized with plasmid DNAs encoding influenza virus haemagglutinin, neuraminidase and nucleoprotein. J. Gen. Virol.80(Pt 10), 2559–2564 (1999).
   PubMed Web of Science ®Google Scholar
• Varghese JN, Colman PM. Three-dimensional structure of the neuraminidase of influenza virus A/Tokyo/3/67 at 2.2 A resolution. J. Mol. Biol.221(2), 473–486 (1991).
   PubMed Web of Science ®Google Scholar
• Johansson BE, Bucher DJ, Kilbourne ED. Purified influenza virus hemagglutinin and neuraminidase are equivalent in stimulation of antibody response but induce contrasting types of immunity to infection. J. Virol.63(3), 1239–1246 (1989).
   PubMed Web of Science ®Google Scholar
• Gubareva LV, Kaiser L, Hayden FG. Influenza virus neuraminidase inhibitors. Lancet355(9206), 827–835 (2000).
   PubMed Web of Science ®Google Scholar
• Kendal AP, Bozeman FM, Ennis FA. Further studies of the neuraminidase content of inactivated influenza vaccines and the neuraminidase antibody responses after vaccination of immunologically primed and unprimed populations. Infect. Immun.29(3), 966–971 (1980).
   PubMed Web of Science ®Google Scholar
• Muhamed G, Greenbaum E, Zakay-Rones Z. Neuraminidase antibody response to inactivated influenza virus vaccine following intranasal and intramuscular vaccination. Isr. Med. Assoc. J.8(3), 155–158 (2006).
   PubMed Web of Science ®Google Scholar
• Powers DC, Kilbourne ED, Johansson BE. Neuraminidase-specific antibody responses to inactivated influenza virus vaccine in young and elderly adults. Clin. Diagn. Lab. Immunol.3(5), 511–516 (1996).
   PubMedGoogle Scholar
• Johansson BE, Pokorny BA, Tiso VA. Supplementation of conventional trivalent influenza vaccine with purified viral N1 and N2 neuraminidases induces a balanced immune response without antigenic competition. Vaccine20(11–12), 1670–1674 (2002).
   PubMed Web of Science ®Google Scholar
• Webster RG, Campbell CH. An inhibition test for identifying the neuraminidase antigen on influenza viruses. Avian Dis.16(5), 1057–1066 (1972).
   PubMed Web of Science ®Google Scholar
• Zalan E, Wilson C, Freitag R. The role of hemagglutinin in the inhibition of neuraminidase activity of influenza virus by concanavalin A. Brief report. Arch. Virol.47(2), 177–179 (1975).
   PubMed Web of Science ®Google Scholar
• Aymard-Henry M, Coleman MT, Dowdle WR, Laver WG, Schild GC, Webster RG. Influenzavirus neuraminidase and neuraminidase-inhibition test procedures. Bull. World Health Organ.48(2), 199–202 (1973).
   PubMed Web of Science ®Google Scholar
• Warren L. The thiobarbituric acid assay of sialic acids. J. Biol. Chem.234(8), 1971–1975 (1959).
   PubMed Web of Science ®Google Scholar
• Luther P, Klett GE, Weber S, Pechmann H, Bergmann KC. The lectin neuraminidase inhibition test: a new method for the detection of antibodies to neuraminidase. J. Biol. Standard.11(2), 115–121 (1983).
   PubMedGoogle Scholar
• Potier M, Mameli L, Belisle M, Dallaire L, Melancon SB. Fluorometric assay of neuraminidase with a sodium (4-methylumbelliferyl-α-D-N-acetylneuraminate) substrate. Anal. Biochem.94(2), 287–296 (1979).
   PubMed Web of Science ®Google Scholar
• Gubareva LV, Robinson MJ, Bethell RC, Webster RG. Catalytic and framework mutations in the neuraminidase active site of influenza viruses that are resistant to 4-guanidino-Neu5Ac2en. J. Virol.71(5), 3385–3390 (1997).
   PubMed Web of Science ®Google Scholar
• Reading PC, Morey LS, Crouch EC, Anders EM. Collectin-mediated antiviral host defense of the lung: evidence from influenza virus infection of mice. J. Virol.71(11), 8204–8212 (1997).
   PubMed Web of Science ®Google Scholar
• Tecle T, White MR, Crouch EC, Hartshorn KL. Inhibition of influenza viral neuraminidase activity by collectins. Arch. Virol.152(9), 1731–1742 (2007).
   PubMed Web of Science ®Google Scholar
• Erickson AH, Kilbourne ED. Comparative amino acid analysis of influenza A viral proteins. Virology100(1), 34–42 (1980).
   PubMed Web of Science ®Google Scholar
• Takahashi T, Suzuki T, Hidari KI, Miyamoto D, Suzuki Y. A molecular mechanism for the low-pH stability of sialidase activity of influenza A virus N2 neuraminidases. FEBS Lett.543(1–3), 71–75 (2003).
   PubMed Web of Science ®Google Scholar
• Johansson BE. Immunization with influenza A virus hemagglutinin and neuraminidase produced in recombinant baculovirus results in a balanced and broadened immune response superior to conventional vaccine. Vaccine17(15–16), 2073–2080 (1999).
   PubMed Web of Science ®Google Scholar
• Brett IC, Johansson BE. Variation in the divalent cation requirements of influenza A virus N1 neuraminidases. J. Biochem.139(3), 439–447 (2006).
   PubMed Web of Science ®Google Scholar
• Johansson BE, Moran TM, Bona CA, Popple SW, Kilbourne ED. Immunologic response to influenza virus neuraminidase is influenced by prior experience with the associated viral hemagglutinin. II. Sequential infection of mice simulates human experience. J. Immunol.139(6), 2010–2014 (1987).
   PubMed Web of Science ®Google Scholar
• Johansson BE, Moran TM, Kilbourne ED. Antigen-presenting B cells and helper T cells cooperatively mediate intravirionic antigenic competition between influenza A virus surface glycoproteins. Proc. Natl Acad. Sci. USA84(19), 6869–6873 (1987).
   PubMed Web of Science ®Google Scholar
• Kilbourne ED, Cerini CP, Khan MW, Mitchell JW Jr, Ogra PL. Immunologic response to the influenza virus neuraminidase is influenced by prior experience with the associated viral hemagglutinin. I. Studies in human vaccinees. J. Immunol.138(9), 3010–3013 (1987).
   PubMed Web of Science ®Google Scholar
• Sever JL. Application of a microtechnique to viral serological investigations. J. Immunol.88, 320–329 (1962).
   PubMed Web of Science ®Google Scholar
• Stephenson I, Nicholson KG, Colegate A et al. Boosting immunity to influenza H5N1 with MF59-adjuvanted H5N3 A/Duck/Singapore/97 vaccine in a primed human population. Vaccine21(15), 1687–1693 (2003).
   PubMed Web of Science ®Google Scholar
• Stephenson I, Wood JM, Nicholson KG, Charlett A, Zambon MC. Detection of anti-H5 responses in human sera by HI using horse erythrocytes following MF59-adjuvanted influenza A/Duck/Singapore/97 vaccine. Virus Res.103(1–2), 91–95 (2004)
   PubMed Web of Science ®Google Scholar
• Stephenson I, Wood JM, Nicholson KG, Zambon MC. Sialic acid receptor specificity on erythrocytes affects detection of antibody to avian influenza haemagglutinin. J. Med. Virol.70(3), 391–398 (2003).
   PubMed Web of Science ®Google Scholar
• Beyer WE, Palache AM, Sprenger MJ et al. Effects of repeated annual influenza vaccination on vaccine sero-response in young and elderly adults. Vaccine14(14), 1331–1339 (1996).
   PubMed Web of Science ®Google Scholar
• Appleyard G, Maber HB. Plaque formation by influenza viruses in the presence of trypsin. J. Gen. Virol.25(3), 351–357 (1974).
   PubMed Web of Science ®Google Scholar
• Zakay-Rones Z, Margalith E, Levy R, Katz E. A sensitive plaque inhibition technique for assay of antibodies to influenza virus: use to detect previous antigenic priming with influenza viruses. J. Virol. Methods1(6), 355–360 (1980).
   PubMed Web of Science ®Google Scholar
• Gross PA, Davis AE. Neutralization test in influenza: use in individuals without hemagglutination inhibition antibody. J. Clin. Microbiol.10(3), 382–384 (1979).
   PubMed Web of Science ®Google Scholar
• Lee MS, Mahmood K, Adhikary L et al. Measuring antibody responses to a live attenuated influenza vaccine in children. Pediatr. Infect. Dis. J.23(9), 852–856 (2004).
   PubMed Web of Science ®Google Scholar
• Frank AL, Puck J, Hughes BJ, Cate TR. Microneutralization test for influenza A and B and parainfluenza 1 and 2 viruses that uses continuous cell lines and fresh serum enhancement. J. Clin. Microbiol.12(3), 426–432 (1980).
   PubMed Web of Science ®Google Scholar
• Rowe T, Abernathy RA, Hu-Primmer J et al. Detection of antibody to avian influenza A (H5N1) virus in human serum by using a combination of serologic assays. J. Clin. Microbiol.37(4), 937–943 (1999).
   PubMed Web of Science ®Google Scholar
• Taylor HP, Dimmock NJ. Mechanism of neutralization of influenza virus by secretory IgA is different from that of monomeric IgA or IgG. J. Exp. Med.161(1), 198–209 (1985).
   PubMed Web of Science ®Google Scholar
• Asahi Y, Yoshikawa T, Watanabe I et al. Protection against influenza virus infection in polymeric Ig receptor knockout mice immunized intranasally with adjuvant-combined vaccines. J. Immunol.168(6), 2930–2938 (2002).
   PubMed Web of Science ®Google Scholar
• Boyce TG, Hsu HH, Sannella EC et al. Safety and immunogenicity of adjuvanted and unadjuvanted subunit influenza vaccines administered intranasally to healthy adults. Vaccine19(2–3), 217–226 (2000).
   PubMed Web of Science ®Google Scholar
• Kiderman A, Furst A, Stewart B, Greenbaum E, Morag A, Zakay-Rones Z. A double-blind trial of a new inactivated, trivalent, intra-nasal anti-influenza vaccine in general practice: relationship between immunogenicity and respiratory morbidity over the winter of 1997–1998. J. Clin. Virol.20(3), 155–161 (2001).
   PubMed Web of Science ®Google Scholar
• Greenbaum E, Furst A, Kiderman A et al. Serum and mucosal immunologic responses in children following the administration of a new inactivated intranasal anti-influenza vaccine. J. Med. Virol.65(1), 178–184 (2001).
   PubMed Web of Science ®Google Scholar
• Greenbaum E, Engelhard D, Levy R, Schlezinger M, Morag A, Zakay-Rones Z. Mucosal (sIgA) and serum (IgG) immunologic responses in young adults following intranasal administration of one or two doses of inactivated, trivalent anti-influenza vaccine. Vaccine22(20), 2566–2577 (2004).
   PubMed Web of Science ®Google Scholar
• Wright PF, Murphy BR, Kervina M, Lawrence EM, Phelan MA, Karzon DT. Secretory immunological response after intranasal inactivated influenza A virus vaccinations: evidence for immunoglobulin A memory. Infect. Immun.40(3), 1092–1095 (1983).
   PubMed Web of Science ®Google Scholar
• Voller A, Bidwell DE, Bartlett A. Enzyme immunoassays in diagnostic medicine. Theory and practice. Bull. World Health Organ.53(1), 55–65 (1976).
   PubMed Web of Science ®Google Scholar
• Tamura S, Miyata K, Matsuo K et al. Acceleration of influenza virus clearance by Th1 cells in the nasal site of mice immunized intranasally with adjuvant-combined recombinant nucleoprotein. J. Immunol.156(10), 3892–3900 (1996).
   PubMed Web of Science ®Google Scholar
• Thomas PG, Keating R, Hulse-Post DJ, Doherty PC. Cell-mediated protection in influenza infection. Emerg. Infect. Dis.12(1), 48–54 (2006).
   PubMed Web of Science ®Google Scholar
• Rimmelzwaan GF, Fouchier RA, Osterhaus AD. Influenza virus-specific cytotoxic T lymphocytes: a correlate of protection and a basis for vaccine development. Curr. Opin. Biotechnol.18(6), 529–536 (2007).
   PubMed Web of Science ®Google Scholar
• McMichael AJ, Gotch FM, Noble GR, Beare PA. Cytotoxic T-cell immunity to influenza. N. Engl. J. Med.309(1), 13–17 (1983).
   PubMed Web of Science ®Google Scholar
• Gianfrani C, Oseroff C, Sidney J, Chesnut RW, Sette A. Human memory CTL response specific for influenza A virus is broad and multispecific. Hum. Immunol.61(5), 438–452 (2000).
   PubMed Web of Science ®Google Scholar
• Wraith DC, Vessey AE, Askonas BA. Purified influenza virus nucleoprotein protects mice from lethal infection. J. General Virol.68(Pt 2), 433–440 (1987).
   PubMed Web of Science ®Google Scholar
• Altstein AD, Gitelman AK, Smirnov YA et al. Immunization with influenza A NP-expressing vaccinia virus recombinant protects mice against experimental infection with human and avian influenza viruses. Arch. Virol.151(5), 921–931 (2006).
   PubMed Web of Science ®Google Scholar
• Fleischer B, Becht H, Rott R. Recognition of viral antigens by human influenza A virus-specific T lymphocyte clones. J. Immunol.135(4), 2800–2804 (1985).
   PubMed Web of Science ®Google Scholar
• Shapira-Nahor O, Morag A, Levy R, Zakay-Rones Z. Cellular response in humans following vaccination with Gripax influenza virus. J. Med. Virol.10(1), 75–80 (1982).
   PubMed Web of Science ®Google Scholar
• Shapira-Nahor O, Zakay-Rones Z. Local and peripheral cell-mediated immune response to influenza virus in mice. J. Med. Virol.15(1), 81–91 (1985).
   PubMed Web of Science ®Google Scholar
• He XS, Holmes TH, Zhang C et al. Cellular immune responses in children and adults receiving inactivated or live attenuated influenza vaccines. J. Virol.80(23), 11756–11766 (2006).
   PubMed Web of Science ®Google Scholar
• Moffat JM, Gebhardt T, Doherty PC, Turner SJ, Mintern JD. Granzyme A expression reveals distinct cytolytic CTL subsets following influenza A virus infection. Eur. J. Immunol.39(5), 1203–1210 (2009).
   PubMed Web of Science ®Google Scholar
• Ennis FA, Rook AH, Qi YH et al. HLA restricted virus-specific cytotoxic T-lymphocyte responses to live and inactivated influenza vaccines. Lancet2(8252), 887–891 (1981).
   PubMed Web of Science ®Google Scholar
• Epstein SL, Kong WP, Misplon JA et al. Protection against multiple influenza A subtypes by vaccination with highly conserved nucleoprotein. Vaccine23(46–47), 5404–5410 (2005).
   PubMed Web of Science ®Google Scholar
• Mabrouk T, Ellis RW. Influenza vaccine technologies and the use of the cell-culture process (cell-culture influenza vaccine). Dev. Biol.110, 125–134 (2002).
   Google Scholar
• Robertson JS, Nicolson C, Major D, Robertson EW, Wood JM. The role of amniotic passage in the egg-adaptation of human influenza virus is revealed by haemagglutinin sequence analyses. J. Gen. Virol.74(Pt 10), 2047–2051 (1993).
   PubMed Web of Science ®Google Scholar
• Oxford JS, Corcoran T, Knott R et al. Serological studies with influenza A(H1N1) viruses cultivated in eggs or in a canine kidney cell line (MDCK). Bull. World Health Organ.65(2), 181–187 (1987).
   PubMed Web of Science ®Google Scholar
• Katz JM, Naeve CW, Webster RG. Host cell-mediated variation in H3N2 influenza viruses. Virology156(2), 386–395 (1987).
   PubMed Web of Science ®Google Scholar
• Doroshenko A, Halperin SA. Trivalent MDCK cell culture-derived influenza vaccine Optaflu (Novartis Vaccines). Expert Rev. Vaccines8(6), 679–688 (2009).
   PubMed Web of Science ®Google Scholar
• Palache AM, Brands R, van Scharrenburg GJ. Immunogenicity and reactogenicity of influenza subunit vaccines produced in MDCK cells or fertilized chicken eggs. J. Infect. Dis.176(Suppl. 1), S20–S23 (1997).
   Web of Science ®Google Scholar
• Kistner O, Barrett PN, Mundt W, Reiter M, Schober-Bendixen S, Dorner F. Development of a mammalian cell (Vero) derived candidate influenza virus vaccine. Vaccine16(9–10), 960–968 (1998).
   PubMed Web of Science ®Google Scholar
• Koudstaal W, Hartgroves L, Havenga M et al. Suitability of PER.C6 cells to generate epidemic and pandemic influenza vaccine strains by reverse genetics. Vaccine27(19), 2588–2593 (2009).
   PubMed Web of Science ®Google Scholar
• Pau MG, Ophorst C, Koldijk MH, Schouten G, Mehtali M, Uytdehaag F. The human cell line PER.C6 provides a new manufacturing system for the production of influenza vaccines. Vaccine19(17–19), 2716–2721 (2001).
   PubMed Web of Science ®Google Scholar
• European Directorate for the Quality of Medicines. European Pharmacopeaia (3rd Edition), 0159. Council of Europe, Strasbourg, France (1997).
   Google Scholar
• Heiny AT, Miotto O, Srinivasan KN et al. Evolutionarily conserved protein sequences of influenza a viruses, avian and human, as vaccine targets. PloS One2(11), e1190 (2007).
   PubMed Web of Science ®Google Scholar
• Neirynck S, Deroo T, Saelens X, Vanlandschoot P, Jou WM, Fiers W. A universal influenza A vaccine based on the extracellular domain of the M2 protein. Nat. Med.5(10), 1157–1163 (1999).
   PubMed Web of Science ®Google Scholar
• Fan J, Liang X, Horton MS et al. Preclinical study of influenza virus A M2 peptide conjugate vaccines in mice, ferrets, and rhesus monkeys. Vaccine22(23–24), 2993–3003 (2004).
   PubMed Web of Science ®Google Scholar
• Fiers W, De Filette M, Birkett A, Neirynck S, Min Jou W. A ‘universal’ human influenza A vaccine. Virus Res.103(1–2), 173–176 (2004).
   PubMed Web of Science ®Google Scholar
• Jegerlehner A, Schmitz N, Storni T, Bachmann MF. Influenza A vaccine based on the extracellular domain of M2: weak protection mediated via antibody-dependent NK cell activity. J. Immunol.172(9), 5598–5605 (2004).
   PubMed Web of Science ®Google Scholar
• Treanor JJ, Tierney EL, Zebedee SL, Lamb RA, Murphy BR. Passively transferred monoclonal antibody to the M2 protein inhibits influenza A virus replication in mice. J. Virol.64(3), 1375–1377 (1990).
   PubMed Web of Science ®Google Scholar
• Mozdzanowska K, Maiese K, Furchner M, Gerhard W. Treatment of influenza virus-infected SCID mice with nonneutralizing antibodies specific for the transmembrane proteins matrix 2 and neuraminidase reduces the pulmonary virus titer but fails to clear the infection. Virology254(1), 138–146 (1999).
   PubMed Web of Science ®Google Scholar
• De Filette M, Min Jou W,Birkett A et al. Universal influenza A vaccine: optimization of M2-based constructs. Virology337(1), 149–161 (2005).
   PubMed Web of Science ®Google Scholar
• Hatta M, Kawaoka Y. The NB protein of influenza B virus is not necessary for virus replication in vitro.J. Virol.77(10), 6050–6054 (2003).
   PubMed Web of Science ®Google Scholar
• Kemble G, Greenberg H. Novel generations of influenza vaccines. Vaccine21(16), 1789–1795 (2003).
   PubMed Web of Science ®Google Scholar
• Paterson RG, Takeda M, Ohigashi Y, Pinto LH, Lamb RA. Influenza B virus BM2 protein is an oligomeric integral membrane protein expressed at the cell surface. Virology306(1), 7–17 (2003).
   PubMed Web of Science ®Google Scholar
• Okuno Y, Isegawa Y, Sasao F, Ueda S. A common neutralizing epitope conserved between the hemagglutinins of influenza A virus H1 and H2 strains. J. Virol.67(5), 2552–2558 (1993).
   PubMed Web of Science ®Google Scholar
• Gschoesser C, Almanzar G, Hainz U et al. CD4+ and CD8+ mediated cellular immune response to recombinant influenza nucleoprotein. Vaccine20(31–32), 3731–3738 (2002).
   PubMed Web of Science ®Google Scholar
• Zhirnov OP, Isaeva EI, Konakova TE et al. Protection against mouse and avian influenza A strains via vaccination with a combination of conserved proteins NP, M1 and NS1. Influenza Other Resp. Viruses1(2), 71–79 (2007).
   PubMed Web of Science ®Google Scholar
• Chen Z, Kadowaki S, Hagiwara Y et al. Protection against influenza B virus infection by immunization with DNA vaccines. Vaccine19(11–12), 1446–1455 (2001).
   PubMed Web of Science ®Google Scholar
• Schotsaert M, De Filette M, Fiers W, Saelens X. Universal M2 ectodomain-based influenza A vaccines: preclinical and clinical developments. Expert Rev. Vaccines8(4), 499–508 (2009).
   PubMed Web of Science ®Google Scholar
• Fodor E, Devenish L, Engelhardt OG, Palese P, Brownlee GG, Garcia-Sastre A. Rescue of influenza A virus from recombinant DNA. J. Virol.73(11), 9679–9682 (1999).
   PubMed Web of Science ®Google Scholar
• Neumann G, Watanabe T, Ito H et al. Generation of influenza A viruses entirely from cloned cDNAs. Proc. Natl Acad. Sci. USA96(16), 9345–9350 (1999).
   PubMed Web of Science ®Google Scholar
• Keitel WA, Treanor JJ, El Sahly HM et al. Comparative immunogenicity of recombinant influenza hemagglutinin (rHA) and trivalent inactivated vaccine (TIV) among persons > or =65 years old. Vaccine28(2), 379–385 (2009).
   PubMed Web of Science ®Google Scholar
• Slepushkin VA, Katz JM, Black RA, Gamble WC, Rota PA, Cox NJ. Protection of mice against influenza A virus challenge by vaccination with baculovirus-expressed M2 protein. Vaccine13(15), 1399–1402 (1995).
   PubMed Web of Science ®Google Scholar
• Cox MM, Karl Anderson D. Production of a novel influenza vaccine using insect cells: protection against drifted strains. Influenza Other Resp. Viruses1(1), 35–40 (2007).
   PubMed Web of Science ®Google Scholar
• Ulmer JB, Donnelly JJ, Parker SE et al. Heterologous protection against influenza by injection of DNA encoding a viral protein. Science (NY)259(5102), 1745–1749 (1993).
   PubMed Web of Science ®Google Scholar
• Ulmer JB. Influenza DNA vaccines. Vaccine20(Suppl. 2), S74–S76 (2002).
   Web of Science ®Google Scholar
• Kodihalli S, Kobasa DL, Webster RG. Strategies for inducing protection against avian influenza A virus subtypes with DNA vaccines. Vaccine18(23), 2592–2599 (2000).
   PubMed Web of Science ®Google Scholar
• Epstein SL, Tumpey TM, Misplon JA et al. DNA vaccine expressing conserved influenza virus proteins protective against H5N1 challenge infection in mice. Emerg. Infect. Dis.8(8), 796–801 (2002).
   PubMed Web of Science ®Google Scholar
• Qiu M, Fang F, Chen Y et al. Protection against avian influenza H9N2 virus challenge by immunization with hemagglutinin- or neuraminidase-expressing DNA in BALB/c mice. Biochem. Biophys. Res. Commun.343(4), 1124–1131 (2006).
   PubMed Web of Science ®Google Scholar
• Laddy DJ, Yan J, Corbitt N, Kobasa D, Kobinger GP, Weiner DB. Immunogenicity of novel consensus-based DNA vaccines against avian influenza. Vaccine25(16), 2984–2989 (2007).
   PubMed Web of Science ®Google Scholar
• Choi SY, Suh YS, Cho JH, Jin HT, Chang J, Sung YC. Enhancement of DNA vaccine-induced immune responses by influenza virus NP gene. Immune Network9(5), 169–178 (2009).
   PubMedGoogle Scholar
• Drape RJ, Macklin MD, Barr LJ, Jones S, Haynes JR, Dean HJ. Epidermal DNA vaccine for influenza is immunogenic in humans. Vaccine24(21), 4475–4481 (2006).
   PubMed Web of Science ®Google Scholar
• Musiychuk K, Stephenson N, Bi H et al. A launch vector for the production of vaccine antigens in plants. Influenza Other Resp. Viruses1(1), 19–25 (2007).
   PubMed Web of Science ®Google Scholar
• Mett V, Musiychuk K, Bi H et al. A plant-produced influenza subunit vaccine protects ferrets against virus challenge. Influenza Other Resp. Viruses2(1), 33–40 (2008).
   PubMed Web of Science ®Google Scholar
• Tosh PK, Poland GA. Emerging vaccines for influenza. Expert Opin. Emerg. Drugs13(1), 21–40 (2008).
   PubMed Web of Science ®Google Scholar
• Mozdzanowska K, Feng J, Eid M et al. Induction of influenza type A virus-specific resistance by immunization of mice with a synthetic multiple antigenic peptide vaccine that contains ectodomains of matrix protein 2. Vaccine21(19–20), 2616–2626 (2003).
   PubMed Web of Science ®Google Scholar
• Mozdzanowska K, Zharikova D, Cudic M, Otvos L, Gerhard W. Roles of adjuvant and route of vaccination in antibody response and protection engendered by a synthetic matrix protein 2-based influenza A virus vaccine in the mouse. Virol. J.4, 118 (2007).
   PubMed Web of Science ®Google Scholar
• Laddy DJ, Yan J, Kutzler M et al. Heterosubtypic protection against pathogenic human and avian influenza viruses via in vivo electroporation of synthetic consensus DNA antigens. PloS One3(6), e2517 (2008).
   PubMed Web of Science ®Google Scholar
• Arnon A, Levi R. Synthetic recombinant vaccines against viral agents. Int. Arch. Allergy Immunol.108(4), 321–326 (1995).
   PubMed Web of Science ®Google Scholar
• Jeon SH, Ben-Yedidia T, Arnon R. Intranasal immunization with synthetic recombinant vaccine containing multiple epitopes of influenza virus. Vaccine20(21–22), 2772–2780 (2002).
   PubMed Web of Science ®Google Scholar
• Lindblad EB. Aluminium compounds for use in vaccines. Immunol. Cell Biol.82(5), 497–505 (2004).
   PubMed Web of Science ®Google Scholar
• Nicholson KG, Colegate AE, Podda A et al. Safety and antigenicity of non-adjuvanted and MF59-adjuvanted influenza A/Duck/Singapore/97 (H5N3) vaccine: a randomised trial of two potential vaccines against H5N1 influenza. Lancet357(9272), 1937–1943 (2001).
   PubMed Web of Science ®Google Scholar
• Banzhoff A, Gasparini R, Laghi-Pasini F et al. MF59-adjuvanted H5N1 vaccine induces immunologic memory and heterotypic antibody responses in non-elderly and elderly adults. PloS One4(2), e4384 (2009).
   PubMed Web of Science ®Google Scholar
• Banzhoff A, Nacci P, Podda A. A new MF59-adjuvanted influenza vaccine enhances the immune response in the elderly with chronic diseases: results from an immunogenicity meta-analysis. Gerontology49(3), 177–184 (2003).
   PubMed Web of Science ®Google Scholar
• Vesikari T, Pellegrini M, Karvonen A et al. Enhanced immunogenicity of seasonal influenza vaccines in young children using MF59 adjuvant. Pediatr. Infect. Dis. J.28(7), 563–571 (2009).
   PubMed Web of Science ®Google Scholar
• Johansen K, Nicoll A, Ciancio BC, Kramarz P. Pandemic influenza A(H1N1) 2009 vaccines in the European Union. Euro Surveill.14(41), 19361 (2009).
   PubMedGoogle Scholar
• Minutello M, Senatore F, Cecchinelli G et al. Safety and immunogenicity of an inactivated subunit influenza virus vaccine combined with MF59 adjuvant emulsion in elderly subjects, immunized for three consecutive influenza seasons. Vaccine17(2), 99–104 (1999).
   PubMed Web of Science ®Google Scholar
• Banzhoff A, Pellegrini M, Del Giudice G, Fragapane E, Groth N, Podda A. MF59-adjuvanted vaccines for seasonal and pandemic influenza prophylaxis. Influenza Other Resp. Viruses2(6), 243–249 (2008).
   PubMed Web of Science ®Google Scholar
• Waddington CS, Walker WT, Oeser C et al. Safety and immunogenicity of AS03B adjuvanted split virion versus non-adjuvanted whole virion H1N1 influenza vaccine in UK children aged 6 months-12 years: open label, randomised, parallel group, multicentre study. Br. Med. J.340, c2649 (2010).
   PubMed Web of Science ®Google Scholar
• Malherbe L, Mark L, Fazilleau N, McHeyzer-Williams LJ, McHeyzer-Williams MG. Vaccine adjuvants alter TCR-based selection thresholds. Immunity28(5), 698–709 (2008).
   PubMed Web of Science ®Google Scholar
• Bungener L, Geeraedts F, Ter Veer W, Medema J, Wilschut J, Huckriede A. Alum boosts TH2-type antibody responses to whole-inactivated virus influenza vaccine in mice but does not confer superior protection. Vaccine26(19), 2350–2359 (2008).
   PubMed Web of Science ®Google Scholar
• Wack A, Baudner BC, Hilbert AK et al. Combination adjuvants for the induction of potent, long-lasting antibody and T-cell responses to influenza vaccine in mice. Vaccine26(4), 552–561 (2008).
   PubMed Web of Science ®Google Scholar
• Babai I, Samira S, Barenholz Y, Zakay-Rones Z, Kedar E. A novel influenza subunit vaccine composed of liposome-encapsulated haemagglutinin/neuraminidase and IL-2 or GM-CSF. II. Induction of TH1 and TH2 responses in mice. Vaccine17(9–10), 1239–1250 (1999).
   PubMed Web of Science ®Google Scholar
• Babai I, Samira S, Barenholz Y, Zakay-Rones Z, Kedar E. A novel influenza subunit vaccine composed of liposome-encapsulated haemagglutinin/neuraminidase and IL-2 or GM-CSF. I. Vaccine characterization and efficacy studies in mice. Vaccine17(9–10), 1223–1238 (1999).
   PubMed Web of Science ®Google Scholar
• Ben-Yehuda A, Joseph A, Zeira E et al. Immunogenicity and safety of a novel liposomal influenza subunit vaccine (INFLUSOME-VAC) in young adults. J. Med. Virol.69(4), 560–567 (2003).
   PubMed Web of Science ®Google Scholar
• Gregoriadis G. Engineering liposomes for drug delivery: progress and problems. Trends Biotechnol.13(12), 527–537 (1995).
   PubMed Web of Science ®Google Scholar
• Gluck R, Mischler R, Finkel B, Que JU, Scarpa B, Cryz SJ Jr. Immunogenicity of new virosome influenza vaccine in elderly people. Lancet344(8916), 160–163 (1994).
   PubMed Web of Science ®Google Scholar
• Gluck R. Adjuvant activity of immunopotentiating reconstituted influenza virosomes (IRIVs). Vaccine17(13–14), 1782–1787 (1999).
   PubMed Web of Science ®Google Scholar
• Zurbriggen R. Immunostimulating reconstituted influenza virosomes. Vaccine21(9–10), 921–924 (2003).
   PubMed Web of Science ®Google Scholar
• Plante M, Jones T, Allard F et al. Nasal immunization with subunit proteosome influenza vaccines induces serum HAI, mucosal IgA and protection against influenza challenge. Vaccine20(1–2), 218–225 (2001).
   PubMed Web of Science ®Google Scholar
• Treanor J, Nolan C, O’Brien D et al. Intranasal administration of a proteosome-influenza vaccine is well-tolerated and induces serum and nasal secretion influenza antibodies in healthy human subjects. Vaccine24(3), 254–262 (2006).
   PubMed Web of Science ®Google Scholar
• Rimmelzwaan GF, Baars M, van Beek R et al. Influenza virus subtype cross-reactivities of haemagglutination inhibiting and virus neutralising serum antibodies induced by infection or vaccination with an ISCOM-based vaccine. Vaccine17(20–21), 2512–2516 (1999).
   PubMed Web of Science ®Google Scholar
• Quan FS, Kim YC, Yoo DG, Compans RW, Prausnitz MR, Kang SM. Stabilization of influenza vaccine enhances protection by microneedle delivery in the mouse skin. PloS One4(9), e7152 (2009).
   PubMed Web of Science ®Google Scholar
• Garg S, Hoelscher M, Belser JA et al. Needle-free skin patch delivery of a vaccine for a potentially pandemic influenza virus provides protection against lethal challenge in mice. Clin. Vaccine Immunol.14(7), 926–928 (2007).
   PubMed Web of Science ®Google Scholar
• Huang J, Garmise RJ, Crowder TM et al. A novel dry powder influenza vaccine and intranasal delivery technology: induction of systemic and mucosal immune responses in rats. Vaccine23(6), 794–801 (2004).
   PubMed Web of Science ®Google Scholar
• Mann JF, Shakir E, Carter KC, Mullen AB, Alexander J, Ferro VA. Lipid vesicle size of an oral influenza vaccine delivery vehicle influences the Th1/Th2 bias in the immune response and protection against infection. Vaccine27(27), 3643–3649 (2009).
   PubMed Web of Science ®Google Scholar
• Quan FS, Kim YC, Vunnava A et al. Intradermal vaccination with influenza virus-like particles by using microneedles induces protection superior to that with intramuscular immunization. J. Virol.84(15), 7760–7769 (2010).
   PubMed Web of Science ®Google Scholar
• Lambert PH, Laurent PE. Intradermal vaccine delivery: will new delivery systems transform vaccine administration? Vaccine26(26), 3197–3208 (2008).
   PubMed Web of Science ®Google Scholar
• Glezen WP, Taber LH, Frank AL, Gruber WC, Piedra PA. Influenza virus infections in infants. Pediatr. Infect. Dis. J.16(11), 1065–1068 (1997).
   PubMed Web of Science ®Google Scholar
• Loeb M, Russell ML, Moss L et al. Effect of influenza vaccination of children on infection rates in Hutterite communities: a randomized trial. JAMA303(10), 943–950 (2010).
   PubMed Web of Science ®Google Scholar
• Rhorer J, Ambrose CS, Dickinson S et al. Efficacy of live attenuated influenza vaccine in children: a meta-analysis of nine randomized clinical trials. Vaccine27(7), 1101–1110 (2009).
   PubMed Web of Science ®Google Scholar